• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK Commits in Big Way to R&D in China

GSK Commits in Big Way to R&D in China

November 10, 2008
CenterWatch Staff

GlaxoSmithKline (GSK) has made a big investment in China, betting that the future of drug development will be led by that country.

In his keynote address, "From ‘Made in China’ to ‘Discovered in China,’" at the China Trials 2008 Global Clinical Development Summit in Shanghai, Perry Nisen, M.D., Ph.D., senior vice president, Cancer Research at GlaxoSmithKline (GSK), emphasized the importance of China with regard to GSK’s global strategy. Nisen said that if GSK’s China initiative is not successful, “it is going to hurt the company” because it has invested so much there. “Our decision was that we really wanted to do it from the beginning to the end.”

While describing GSK’s globalization priorities—talent, innovation/technology, patients, market access and cost—Nisen remarked more than once that he was impressed by the “magnitude of the slope of change” in China. He specifically noted the dramatic increase in the talent pool for R&D as well as the “sea turtle” phenomenon, a reference to Ph.D. students who study abroad and then return to China to become investigators. Nisen said one of the reasons that convinced GSK to invest in China was that the number of Ph.D.s in China was rising at a much faster rate than in the U.S. and other countries.

With the increase in talent, Nisen commented that there were examples of research institutes that were “starting to rival research institutes in the U.S. and Western Europe.”

GSK established an end-to-end fully integrated R&D center for the purpose of  developing novel medicines for global registration a year and a half ago. “Unless we established an end-to-end unit, how would we attract talent within China, how would we attract talent from other parts of the world and from other parts of GSK?”

GSK already has 200 staff there. The R&D center provides GSK with a strategic presence in Asia. “It feels like a biotech,” said Nisen, adding, “There is an intense feel of excited, passionate scientists.”

Several speakers at the conference made the point that drug development in China is changing so rapidly, it’s hard to keep up.

GSK is not the only Big Pharma to set up an R&D center in China. It followed Roche, Pfizer, AstraZeneca and Novartis. Eli Lilly and Company also set up an R&D center around the same time.

Many challenges to having a smooth R&D process in China remain, however. They are: the inability to send human material outside the country, long regulatory approval timelines, incomplete intellectual property protection, world economic slowdown, language and culture.

However, GSK’s investment illustrates the positive outlook for China’s future. “There is every aspect of R&D in China,” Nisen said. “Some elements are reasonably mature and others are sophisticated at a global level.” He also stressed that what is not a core capability in China today, one could expect to be in future.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing